Drug intelligence / Profile preview

ImSAF

Development stage: Discontinued
Lead developer: VG Life Sciences
Modality: Peptides
Administration: Topical

Overview

ImSAF (Immunological Skin and Autoimmune Formula) is a topical immunomodulator developed by VG Life Sciences (formerly Viral Genetics) for the treatment of autoimmune and inflammatory skin conditions. The therapy was designed to modulate local immune responses in the skin, leveraging the company's research into peptide-based immune regulation. VG Life Sciences' core technology involved 'Targeted Peptides' that aimed to influence the MHC Class II antigen-associated invariant chain (Ii) to redirect the immune system and alleviate inflammation. Development of ImSAF has ceased following the company's transition out of the biotechnology sector and the abandonment of its pharmaceutical pipeline.

Other names: Immunological Skin and Autoimmune Formula

Targets

γδ TCR (T-cell receptor)CLIP (Class II-associated invariant chain peptide)

Beyond the preview

Go deeper on ImSAF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImSAF.

Explore the full profile